Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Resource
  2. Source: Campus Sanofi
  3. 1 Aug 2026
15 min

Dupixent (dupilumab) Resources

Author: Sanofi

Find additional DUPIXENT resources here

Dupixent (dupilumab) Prescribing Information UK

Expert Presentations

Dupixent in patients as young as 6 months old with severe AD – expert panel discussions

Watch a panel of experts discuss the practicalities of using DUPIXENT in children aged <12 years through real-world case studies.

 Video Playtime: 48mins 05secs

Patient Case Studies

DUPIXENT use in a 3-year old patient – Dr. Gabriela Petrof

Watch Dr. Gabriela Petrof present a case study of the use of DUPIXENT in a 3-year old patient with severe atopic dermatitis.

Video Playtime: 7mins 07secs

DUPIXENT use in a child patient with severe AD – Dr. Inge Kreuzer-Genis & Emily King

Watch Dr. Inge Kreuzer-Genis and Emily King present a clinical case study of the use of DUPIXENT in an 8-year old patient with severe atopic dermatitis.

Video Playtime: 13mins 52secs

Conjunctivitis Management

Conjunctivitis Management - Mr Scott Robbie

Watch Mr Scott Robbie discuss management of conjunctivitis in AD patients.

Video Playtime: 1min 45secs

Patient Guides

Please click below for available patient guides for patients prescribed with Dupixent: 

AD and Dupixent
Welcome to Dupixent
Photo of the paper ADCT test

Atopic Dermatitis Control Test (ADCT)

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

Try the ADCT

MAT-XU-2304411 (v5.0) Date of Preparation: August 2026  

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025